Clinical trial · Interventional
Study of Lymphatic Drainage Mapping in Oropharyngeal Cancers
A Feasibility Trial of Lymphatic Mapping With SPECT-CT for Evaluating Contralateral Disease in Lateralized Oropharynx Cancer Using 99m-Technetium Sulfur Colloid
NCT05055206CI-TRIAL-00098323completedN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
The purpose of the study is to see how practical it is to inject a radiotracer called 99m-Technetium Sulfur Colloid around the tumors for the imaging of patients with oropharyngeal cancer.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Oropharynx Cancer | Malignant Oropharyngeal Neoplasm | ALIAS | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| SPECT-CT | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (1)
- type
- EXPERIMENTAL
- label
- Lymphatic drainage mapping in patients with oropharynx cancer
- description
- Participants will be given 4 to 6 injections of the radiotracer 99m-Technetium Sulfur Colloid by a needle into one of the veins of the radiotracer around the tumour. Participants will then have at least 1 or possibly 2 SPECT-CT scans (a special x-ray scan of the body from many angles that are turned into 3-dimensional pictures on a screen).
- interventionNames
- Diagnostic Test: SPECT-CT
Primary outcomes (9)
- measure
- Proportion of patients injected with radiotracer.
- timeFrame
- 1 year
- measure
- Proportion of patients requiring general anesthetic over local anesthetic.
- timeFrame
- 1 year
- measure
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Patient has lateralized oropharyngeal carcinoma (tonsil or tongue base) not involving midline * Has squamous cell carcinoma, T1-3 tumours, with no contralateral nodes on clinical exam or axial imaging * Human papillomavirus (HPV) positive or negative * Patient should have normal organ function as per Investigator judgement * Patient is planned for definitive or adjuvant radiotherapy (RT) or chemo radiotherapy (CRT) with bilateral neck RT, or surgery * Eastern Cooperative Oncology Group (ECOG) performance status 0-1 Exclusion Criteria: * T4 tumours * Contralateral/bilateral nodal disease or node(s) \> 6cm on clinical exam or axial imaging or positron emission tomography (PET) * Primary tumour involving or crossing midline * Soft palate or posterior pharyngeal wall tumour subsites * Previous head and neck cancer * Previous radiotherapy (RT) to the head and neck * Previous neck dissection * Distant metastases * Prior invasive malignancy (except non-melanoma skin cancer) unless disease free for 3 years * Prior radiotracer allergy * Multiple primary head and neck cancers * Pregnancy
References
Publications (0)
Data not yet available
No reference posted for this study.